Health Trials

DLBCL Unclassifiable

2

Review clinical trials related to DLBCL Unclassifiable. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Participants needed: 146
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Apr 17, 2026Locations: 29
Eligibility criteria

Provision of signed and dated written informed consent prior to any study [+5]

Prior malignancy (other than the disease under study) within the past 2 years, e... [+4]

Read more
Status: Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Feb 17, 2026Locations: 7
Eligibility criteria

While prior CD19-targeted therapies, including CAR T-cell therapy, do not exclud... [+8]

ECOG performance status ≥3. [+15]

Read more